Erratum to: J. Neurovirol. (2017) 23:335–337
DOI 10.1007/s13365-016-0489-5
We apologize for the mistake which slipped through all careful reading and re-reading: it must, correctly, read throughout the entire paper ... foscarnet i.v. 60 mg per kg bodyweight (b.w.), t.i.d.
It is correct that 40 mg/kg b.w. is the recommended daily dose (Chilukuri and Rosen 2011), but in view of the dramatic clinical and neuro-imaging course we opted for an increased dose carefully monitoring for side effects.
Footnotes
The online version of the original article can be found at 10.1007/s13365-016-0489-5
References
- Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E (2017) Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. J Neurovirol 23(2):335–337 [DOI] [PMC free article] [PubMed]
- Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311–320. doi: 10.1016/S0733-8635(02)00093-1. [DOI] [PubMed] [Google Scholar]